These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22431305)

  • 1. Long-term luminal change after drug-eluting stent implantation: serial angiographic follow-up study of the ZEST randomized trial.
    Park GM; Park DW; Kim YG; Cho SW; Sun BJ; Hwang KW; Kim YR; Ahn JM; Song HG; Kim WJ; Lee JY; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):274-82. PubMed ID: 22431305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
    Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ
    Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Kirtane AJ; Patel R; O'Shaughnessy C; Overlie P; McLaurin B; Solomon S; Mauri L; Fitzgerald P; Popma JJ; Kandzari DE; Leon MB
    JACC Cardiovasc Interv; 2009 Oct; 2(10):967-76. PubMed ID: 19850257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
    Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L
    JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neointimal response to second-generation drug-eluting stents in diabetic patients with de-novo coronary lesions: intravascular ultrasound study.
    Won H; Kang TS; Hong BK; Lee S; Jeon DW; Ryu SK; Min PK; Yoon YW; Lee BK; Kwon HM; Ko YG; Jang Y
    Coron Artery Dis; 2015 May; 26(3):212-9. PubMed ID: 25426659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
    JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late catch-up in lumen diameter at five-year angiography in MACE-free patients treated with sirolimus-eluting stents in the Primary Stenting of Totally Occluded Native Coronary Arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II).
    Teeuwen K; Van den Branden BJ; Rahel BM; Laarman GJ; Tijssen JG; Kelder JC; Slagboom T; Ten Berg JM; Suttorp MJ
    EuroIntervention; 2013 Jun; 9(2):212-9. PubMed ID: 23392450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of zotarolimus-eluting stents with sirolimus-eluting and paclitaxel-eluting stents: intimal hyperplasia and vascular changes assessed by volumetric intravascular ultrasound analysis.
    Kang SJ; Mintz GS; Park DW; Lee SW; Kim YH; Lee CW; Han KH; Kim JJ; Park SW; Park SJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):139-45. PubMed ID: 21364151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
    Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
    JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Leon MB; Kandzari DE; Eisenstein EL; Anstrom KJ; Mauri L; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; Kirtane AJ; McLaurin BT; Solomon SL; Douglas JS; Popma JJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1208-18. PubMed ID: 20129547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion.
    Kim U; Kim DK; Seol SH; Yang TH; Kim DK; Kim DI; Kim DS; Lee SH; Hong GR; Park JS; Shin DG; Kim YJ; Cho YK; Kim HS; Nam CW; Hur SH; Kim KB
    Clin Cardiol; 2010 Jun; 33(6):340-4. PubMed ID: 20556803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very long-term serial luminal changes after sirolimus-eluting stent implantation and progression process of very late stent failure.
    Kubo S; Ohya M; Kuwayama A; Shimada T; Miura K; Amano H; Otsuru S; Habara S; Tada T; Tanaka H; Fuku Y; Goto T; Kadota K
    Cardiovasc Revasc Med; 2018; 19(1 Pt B):88-94. PubMed ID: 28778392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.
    Kufner S; Byrne RA; de Waha A; Schulz S; Joner M; Laugwitz KL; Kastrati A;
    Cardiovasc Revasc Med; 2014 Mar; 15(2):69-75. PubMed ID: 24684757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiographic patterns of restenosis with 2nd generation drug-eluting stent: comparative analysis from a 10-year single-center experience .
    Lee S; Yoon CH; Oh IY; Suh JW; Cho YS; Cho GY; Chae IH; Choi DJ; Youn TJ
    Int Heart J; 2015; 56(1):6-12. PubMed ID: 25503656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.